Interface Biologics to Present at ARVO 2019
TORONTO, Canada, April 24, 2019 – Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, will be presenting at The Association for Research in Vision and Ophthalmology 2019 meeting.

Details are as follows:

Title: Pharmacokinetics and pharmacodynamics of a Novel Dexamethasone Intravitreal Implant

Presenter: Baruch D. Kuppermann, MD, PhD, Chair of the Department of Ophthalmology at the UC Irvine School of Medicine and Director of the Gavin Herbert Eye Institute

Date: Monday April 29, 2019

Time: 11:15am-11:30am

Location:  East 2/3 Vancouver Convention Centre

About Interface Biologics, Inc. nterface Biologics (IBI) is an early commercial stage privately held company that develops innovative materials for Medtech and Pharmaceutical applications. IBI surface modification additives are used in FDA-approved medical devices and are clinically proven to reduce infection and thrombus-related complications.  IBI’s sustained local drug delivery technology is applicable across a range of drug classes and medical specialties with an initial focus on ophthalmology.

About ARVO: The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include nearly 12,000 eye and vision researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders. Learn more at

Media Contact: Julie Fotheringham, Partner, Hageman Communications M: 416-951-7988 E:


Powered by Innovasium